Cargando…

Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial

Introduction: Randomized, controlled trials of molnupiravir in real-world use during the Omicron wave are scarce. The frequency of hospitalization and death is low, so further research is needed to confirm the virological efficacy of molnupiravir. Methods: A single-center, randomized, controlled cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yayun, Fan, Shiyong, Xu, Aijing, Ge, Lingling, Wang, Xinyu, Dong, Xu, Xu, Mingxiao, Fan, Wenhan, Zhong, Wu, Liang, Xuesong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687146/ https://www.ncbi.nlm.nih.gov/pubmed/38034986 http://dx.doi.org/10.3389/fphar.2023.1197671

Ejemplares similares

Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir
por: Liu, Yayun, et al.
Publicado: (2022)

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
por: Zou, Rongrong, et al.
Publicado: (2022)

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
por: Li, Pengfei, et al.
Publicado: (2022)

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
por: Rosenke, Kyle, et al.
Publicado: (2022)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
por: Zhang, Yuwei, et al.
Publicado: (2023)

Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model
por: Rosenke, Kyle, et al.
Publicado: (2022)

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
por: Sinha, Shubhadeep, et al.
Publicado: (2022)

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
por: Vangeel, Laura, et al.
Publicado: (2022)

Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review
por: Mali, Kalpana Ramanna, et al.
Publicado: (2022)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
por: Weil, Clara, et al.
Publicado: (2023)

A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant
por: Liu, Changya, et al.
Publicado: (2023)

A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in Chinese participants infected with SARS-CoV-2 Omicron variants
por: Dong, Yidan, et al.
Publicado: (2022)

Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees
por: Yu, Pei, et al.
Publicado: (2023)

Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
por: Suzuki, Yasuhito, et al.
Publicado: (2022)

Molnupiravir; molecular and functional descriptors of mitochondrial safety
por: Wallace, K.B., et al.
Publicado: (2022)

Genetic Epidemiology of Medication Safety and Efficacy Related Variants in the Central Han Chinese Population With Whole Genome Sequencing
por: Tian, Junbo, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
por: Barbui, Tiziano, et al.
Publicado: (2022)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection
por: Gao, Bo, et al.
Publicado: (2023)

Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study
por: Zheng, Qinyue, et al.
Publicado: (2023)

Editorial: Ocular Pharmacology: Recent Breakthroughs and Unmet Needs
por: Bucolo, Claudio, et al.
Publicado: (2022)

In vitro and in vivo efficacy of Molnupiravir against Zika virus infections
por: Wang, Zhuang, et al.
Publicado: (2023)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Efficacy, Safety, and Economics of Intravenous Levetiracetam for Status Epilepticus: A Systematic Review and Meta-Analysis
por: Yi, Zhan-Miao, et al.
Publicado: (2020)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA
por: Keyel, Alexander C., et al.
Publicado: (2022)

SARS-CoV-2 Vaccine Breakthrough Infections of Omicron and Delta Variants in Healthcare Workers
por: Regenhardt, Elisa, et al.
Publicado: (2023)

Thymoquinone’s Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
por: Zhao, Lijuan, et al.
Publicado: (2023)

Editorial: Quality control for efficacy and safety of herbal medicinal products
por: Lam, Wing, et al.
Publicado: (2023)

Omicron breakthrough infections in vaccinated or previously infected hamsters
por: Zhou, Jie, et al.
Publicado: (2023)

Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
por: Qiu, Chaochao, et al.
Publicado: (2023)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a7ossr8ghneovnr3lajtjf3adm